Development of a nanocrystalline paclitaxel formulation for hipec treatment

Pharmaceutical Research

Volumn 29, Issue 9, 2012, Pages 2398-2406

  De Smet, Lieselotte ^a   Colin, Pieter ^a   Ceelen, Wim ^b   Bracke, Marc ^b   Van Bocxlaer, Jan ^a   Remon, Jean Paul ^a   Vervaet, Chris ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hyperthermic intraperitoneal chemotherapy; Nanocrystal; Ovarian cancer; Paclitaxel; Wet milling

Indexed keywords

NANOCRYSTAL; PACLITAXEL; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CARCINOMATOUS PERITONITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; EXPERIMENTAL RAT; FEMALE; HUMAN; HUMAN CELL; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; MAXIMUM TOLERATED DOSE; NANOPHARMACEUTICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CRYSTALLIZATION; FEMALE; MICROSCOPY, ELECTRON; NANOTECHNOLOGY; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; RATS;

EID: 84866736842     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0765-x     Document Type: Article

References (23)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46 (4):765-81.
2. Sugarbaker PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: The Washington Cancer Institute approach. Expert Opin Pharmacother. 2009;10(12):1965-77.
3. Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol. 2011;18(2):E84-96.
4. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis. Gynecol Oncol. 2009;112 (1):265-74.
5. Dovern E, de Hingh I, Verwaal VJ, van Driel WJ, Nienhuijs SW. Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications. Eur J Gynaecol Oncol. 2010;31(3):256-61.
6. Markman M. Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol. 2003;4(5):277-83.
7. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-8.
8. Colson YL, Liu R, Southard EB, Schulz MD, Wade JE, Griset AP, et al. The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis. Biomaterials. 2011;32 (3):832-40.
9. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: Critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010;62(11):1569-79.
10. Kesisoglou F, Panmai S, Wu Y. Application of nanoparticles in oral delivery of immediate release formulations. Current Nanoscience. 2007;3(2):183-90.
11. Liu F, Park J-Y, Zhang Y, Conwell C, Liu Y, Bathula SR, et al. Targeted Cancer Therapy With Novel High Drug-Loading Nanocrystals. J Pharm Sci. 2010;99(8):3542-51.
12. Yeo Y, Ito T, Bellas E, Highley CB, Marini R, Kohane DS. In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions. Ann Surg. 2007;245(5):819-24.
13. Bouquet W, Ceelen W, Adriaens E, Almeida A, Quinten T, De Vos F, et al. In vivo Toxicity and Bioavailability of Taxol (R) and a Paclitaxel/beta- Cyclodextrin Formulation in a Rat Model During HIPEC. Ann Surg Oncol. 2010;17(9):2510-7.
14. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23(12):2709-28.
15. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic((R)) block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev. 2002;54(5):759-79.
16. Batrakova EV, Li S, Brynskikh AM, Sharma AK, Li YL, Boska M, et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release. 2010;143(3):290-301.
17. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorlywater soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63(6):427-40.
18. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409(1-2):260-8.
19. Debree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: A clinical and pharmacokinetic study. Ann Surg Oncol. 2008;15 (4):1183-92.
20. Bajaj G, Yeo Y. Drug delivery systems for intraperitoneal therapy. Pharm Res. 2010;27(5):735-8.
21. Liu P, Rong XY, Laru J, van Veen B, Kiesvaara J, Hirvonen J, et al. Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling. Int J Pharm. 2011;411(1-2):215-22.
22. Tannock IF, Lee CM, Tunggal JK, Cowan DSM, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002;8(3):878-84.
23. Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17(1):1-20.